Skip to main content
. Author manuscript; available in PMC: 2017 Nov 21.
Published in final edited form as: J Am Coll Cardiol. 2015 Jan 6;65(1):1–11. doi: 10.1016/j.jacc.2014.09.078

Table 2.

Cost-Effectiveness Analysis: PSBB Adjusted

Δ
CABG
- PCI		 Life
Years or
QALY
Gained
with
CABG		 ICER %
CABG
Dominated		 % CABG
Dominant		 %
<$30,000
/LYG		 %
<$50,000
/LYG		 %
<$100,000
/LYG
Life years from 2004 through 2008 $8,323 0.1178 $70,647 0 0 0 0 99.0
Life years from 2004 through 2008 (3% discount and PSBB adjusted) $8,088 0.3088 $26,192 0 0 70 97.0 100.0
Lifetime (3% discount and PSBB adjusted) $11,575 0.3016 $38,379 0 0 3.0 91.0 99.0
Quality-adjusted lifetime (3% and PSBB adjusted) $11,575 0.3801 %30,454 0 0 47.0 98.0 100.0

ICER = incremental cost-effectiveness ratio; LYG = life years gained; other abbreviations as in Tables 1 and 2.